Navigation Links
New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief

FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), today announced results from a new phase IV "Open Label" clinical study demonstrating that LidoSite, the first FDA approved active patch for dermal analgesia, provided better pain relief to more than 73 percent of patients receiving injections of hyaluronic acid during treatment for osteoarthritis than usual topical analgesics.

"Treatment can be very painful, requiring multiple injections into sensitive joints, with many patients having a difficult time with this pain, leading some to avoid regular treatment," said Dr. Evan Liebowitz, a rheumatologist affiliated with Prospect Medical Office in Midland Park, NJ and Valley Hospital in Ridgewood, NJ. "Patients who avoid regular treatments for rheumatoid arthritis and osteoarthritis risk further loss of articular cartilage in the knee."

The study, involving six study sites and 14 physicians, followed 63 patients over the course of two routine injections of hyaluronic acid for the treatment of osteoarthritis.

During the first treatment, patients either received no local anesthesia or an alternate local anesthesia prior to cannulation or needle puncture. During the second treatment, patients received the LidoSite system, comprised of the LidoSite Patch and the LidoSite Controller. In the study more than 73 percent preferred LidoSite to the treatment used during their first visit. Additionally, the majority of rheumatology physicians surveyed were satisfied with LidoSite, compared to other available treatment options, such as ethyl chloride, lidocaine injections or fluormethane spray.

"This initial study demonstrates the acceptability among patients and rheumatologists for using LidoSite as an effective treatment regime for needle pain for the multiple injections arthritis requires, as well as its potential availability in the doctor's office setting."
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/27/2014)... 2014 - New Solution That ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC ... 500,000 yen or $5,000 (without tax /including two pairs of ... is a dedicated solution of "JINS MEME" to academic researchers, ... data* generated by electrooculography and six-axis sensors without API. (*Physiological ...
(Date:11/26/2014)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... Products®," today announced the closing of Perrigo,s previously announced ... ordinary shares at a public offering price of $152.00 ... to purchase up to an additional 888,157 ordinary shares ... as representatives of the several underwriters. ...
(Date:11/26/2014)... 26, 2014   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and CEO of Regulus, will present a company overview ... Conference at the New York Palace Hotel on Wednesday, ... will be webcast at the time of the presentation ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3
(Date:11/27/2014)... 27, 2014 Allowing children to help with ... school, helps give children responsibility, ownership, boosts self-esteem, and above ... , Now, the real question is, how do you encourage ... According to a study published by Child Development Journal, there ... dramatic effect on a child’s willingness to lend a hand. ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. "Every ... as we enjoy the ugly sweater contest." Last year's ... " It was a sight to see. She glued ... the Christmas balls were faces of the staff with Dr. ... this year, it's simple to get in on the fun. ...
(Date:11/27/2014)... New Delhi, India (PRWEB) November 27, 2014 ... internet marketing company, has announced online reputation management ... after doing a comprehensive study about the world of ... Google, Bing, and Yahoo. , Ethane Web Technologies ... project. Instead, it first analyzes the project to reach ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Ethane Web Technologies, ... it will provide a 10% Christmas discount on PPC service. ... December. The discount offer will begin on 1 December 2014 ... , About this offer, a PPC professional working at Ethane ... especially for small businesses, as this big discount would make ...
(Date:11/27/2014)... CA, (PRWEB) November 26, 2014 ... browser-based presentation platform, focused on increasing audience engagement ... Britannic Technologies. Lintelus’ software platform includes a multitude ... and presenter in a collaborative, interactive multi-screen environment. ... and the presentation in real time on their ...
Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces Online Reputation Management Service 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2Health News:Lintelus Showcases its Feature-Rich Presentation Technology Solution at Convergence Summit’s Annual Event in London 2
... Lahore have arrested four doctors engaged in the illegally removing ... were made Friday night after police apprehended three middlemen and ... heavily guarded house in the city, Lahore police chief Aftab ... former patient then raided two private hospitals where the four ...
... services have been paralysed in a Bihar district as hundreds of ... police in rescuing two abducted school students who are close ... about 125 km from the state capital, went on a two-day ... Saurav, 12 and Gaurav, 12. Both the boys are student of ...
... case of H5N1 infection known as bird flu in a ... by his surname, Cheng, and said he was under treatment ... it did not specify his unit or say which region ... affairs. ,Cheng developed symptoms of fever, coughing and ...
... identify the places most at risk of devastating earthquakes. ... zones' that can spawn giant quakes, researchers attending a ... Society and several Latin American geophysical associations, claimed that ... a locked zone to the west of Seattle. ...
... Center (BMC) and Boston University School of Public Health ... immunodeficiency virus (HIV), who also have alcohol problems, ... virus (HCV). These findings appear in the June issue ... HIV and HCV is a significant medical and public ...
... cancer is an elevated rate of increase in prostate specific ... study found that a pre-treatment rate of PSA increase, called ... with a high risk of death from prostate cancer. Elevated ... other single high-risk indicator, such as a biopsy Gleason score ...
Cached Medicine News:Health News:Persons With HIV and Alcohol Problems Co-infected With Hepatitis C 2Health News:High Pretreatment PSA Velocity Predicts Worse Outcome 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: